A report on autoimmune CAR-T development highlights how teams are grappling with fatal toxicities that test the field’s safety thesis. Developers point to multiple risk determinants for immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), including manufacturing speed and construct design, as well as patient biology. The focus on IEC-HS reflects ongoing effort to translate CAR-T biology into autoimmune settings where the therapeutic window and inflammatory consequences may differ from oncology. For companies pursuing off-the-shelf or rapid-manufacturing approaches, the article underscores the importance of evidence-based mitigation strategies and robust patient selection. The coverage indicates that safety questions remain central in autoimmune CAR-T programs, where even rare catastrophic events can reshape trial conduct, regulatory engagement, and platform roadmaps.